Cargando…

Correction for: A novel fatty-acid metabolism-based classification for triple negative breast cancer

Detalles Bibliográficos
Autores principales:	Yang, Xia, Tang, Wen, He, Yongtao, An, Huimin, Wang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085610/ https://www.ncbi.nlm.nih.gov/pubmed/36995931 http://dx.doi.org/10.18632/aging.204638

Ejemplares similares

A novel fatty-acid metabolism-based classification for triple negative breast cancer
por: Yang, Xia, et al.
Publicado: (2023)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Correction: Glycogen synthase 1 targeting reveals a metabolic vulnerability in triple-negative breast cancer
por: de Heer, E. C., et al.
Publicado: (2023)

Correction to: Molecular analyses of triple-negative breast cancer in the young and elderly
por: Aine, Mattias, et al.
Publicado: (2021)

Correction: MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017)

Correction: GPR110 promotes progression and metastasis of triple-negative breast cancer
por: Nam, Hye-Jung, et al.
Publicado: (2022)

Correction: triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival
por: Choi, Yoon-La, et al.
Publicado: (2011)

Correction: γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancers
por: Trošt, Nuša, et al.
Publicado: (2019)

Correction: WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer
por: Ertay, Ayse, et al.
Publicado: (2021)

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

Correction: Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer
por: Chapman, Margaret P., et al.
Publicado: (2019)

Fatty acid synthetase expression in triple-negative breast cancer
por: Park, Jin Hee, et al.
Publicado: (2022)

Author Correction: Omega-3 docosahexaenoic acid induces pyroptosis cell death in triple-negative breast cancer cells
por: Pizato, Nathalia, et al.
Publicado: (2018)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Correction: Expression of Dickkopf-1 and Beta-Catenin Related to the Prognosis of Breast Cancer Patients with Triple Negative Phenotype
Publicado: (2014)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publicado: (2021)

Correction: PARP targeted Auger emitter therapy with [(125)I]PARPi-01 for triple-negative breast cancer
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2023)

Correction: Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer
por: Shao, Fuqiang, et al.
Publicado: (2023)

Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2015)

Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
por: Chaudhary, Pankaj, et al.
Publicado: (2020)

Correction to: New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells
por: Ciocan-Cartita, Cristina Alexandra, et al.
Publicado: (2020)

Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021)

Correction: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer
por: Guido, Bruna Cândido, et al.
Publicado: (2022)

Correction: Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential
por: Singh, Balraj, et al.
Publicado: (2022)

Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
por: Nie, Lei, et al.
Publicado: (2020)

Molecular Classification of Triple-Negative Breast Cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2016)

Differences in elongation of very long chain fatty acids and fatty acid metabolism between triple-negative and hormone receptor-positive breast cancer
por: Yamashita, Yuji, et al.
Publicado: (2017)

Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy
por: Zhou, Yu, et al.
Publicado: (2022)

Correction to: Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer
por: Zheng, Shaoquan, et al.
Publicado: (2020)

Correction: BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer
por: Shields, Sarah, et al.
Publicado: (2019)

Correction: M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2
por: Dong, Fang, et al.
Publicado: (2022)

Classification of triple-negative breast cancers based on Immunogenomic profiling
por: He, Yin, et al.
Publicado: (2018)

Author Correction: Triple-negative invasive breast carcinoma: the association between the sonographic appearances with clinicopathological feature
por: Li, Jia-wei, et al.
Publicado: (2020)

Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer
por: Lee, Joyce V., et al.
Publicado: (2022)

MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer
por: Casciano, Jessica C., et al.
Publicado: (2020)

Correction: Pan et al. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer. Cancers 2020, 12, 94
por: Pan, Mei-Ren, et al.
Publicado: (2021)

Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
por: Necela, Brian M., et al.
Publicado: (2015)

Correction: Spectrum of EGFR Gene Copy Number Changes and KRAS Gene Mutation Status in Korean Triple Negative Breast Cancer Patients
Publicado: (2014)

Correction: A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer
por: Vitali, Francesca, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tbsb73gq8vdan8u9qiaqutd861